Global neurodegenerative drugs market set to hit $45 billion by 2022

The neurodegenerative disorders market, which covers Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple sclerosis (MS), is set to grow from $27.2 billion in 2015 to $45 billion by 2022, at a compound annual growth rate of 7.42%.

Business intelligence provider GBI Research’s latest report states that much of this growth is expected to occur between 2018 and 2022, due to the approval of many pipeline products within these years. Indeed, several late-stage products are expected to be highly commercially successful, including ocrelizumab, Roche’s (ROG: SIX) Ocrevus brand, ozanimod, from Celgene (Nasdaq: CELG), solanezumab, from Eli Lilly (NYSE: LLY), ITI-007 and RG-7412.

Qaisrah Khalid, an analyst for GBI Research, explains: “There is a large pharmaceutical pipeline for neurodegenerative disorders, consisting of approximately 1,494 products in active development. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics, or repositioned from other indications – most of which are at Phase I. This indicates progress in terms of different molecules being developed as therapeutic agents within the neurodegenerative pipeline.”